Fig. 5
HDACs/mTOR inhibitor 1 combined with pyrotinib suppresses the growth of CDX and PDX of PDAC. (A-D, F-I) Cell-deived xenografts of AsPC-1 and patient-derived xenografts from PDAC tumors were treated with vehicle, pyrotinib 40 mg/kg, HDACs/mTOR inhibitor 1 10 mg/kg or combined once the tumors reached 50-100mm3 and randomized for 21 days. The tumor volume and body weight were monitored every 2–3 day. Curves of tumor volume were shown in (A) and (F), weight of tumors was shown in (B) and (G), pictures of tumors were shown in (C) and (H), curves of body weight were shown in (D) and (I). E, J Identical pictures of H&E and IHC staining of Ki67 were shown in (E) and (J). Scale bars, 100 μM. Data are represented as mean ± SD. Statistical significance was assessed using a Student t test. *P < 0.05, **P < 0.01, ***P < 0.001. ns not significant